PET-CT Based Radiotherapy in Esophageal Cancer Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2011 by Maastricht Radiation Oncology.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Maastricht Radiation Oncology
ClinicalTrials.gov Identifier:
NCT01156831
First received: July 2, 2010
Last updated: February 8, 2011
Last verified: February 2011

July 2, 2010
February 8, 2011
November 2004
December 2011   (final data collection date for primary outcome measure)
Locoregional control [ Time Frame: 2 years and 5 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01156831 on ClinicalTrials.gov Archive Site
  • Overall Survival [ Time Frame: 2 years and 5 years ] [ Designated as safety issue: No ]
  • Disease Free survival [ Time Frame: 2 years and 5 years ] [ Designated as safety issue: No ]
  • Tumor regression grade [ Time Frame: At the time of surgery ] [ Designated as safety issue: No ]
    Tumor regression grade at time of surgery evaluated by pathologist.
Same as current
Not Provided
Not Provided
 
PET-CT Based Radiotherapy in Esophageal Cancer Patients
Consequences of Positron-Emission-Tomography/Computed Tomography (PET/CT) Based Radiotherapy Treatment Planning for Clinical Outcome in Esophageal Cancer Patients

The purpose of this study is to determine the locoregional control in PET/CT based radiotherapy treatment planning in the treatment of esophageal cancer patients.

The purpose of this study is to determine the locoregional control in PET/CT based radiotherapy treatment planning in the treatment of esophageal cancer patients

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Primary Care Clinic

Esophageal Neoplasms
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
December 2011
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically proven adenocarcinoma or squamous cell carcinoma of the esophagus
  • Local curable disease able to undergo Chemoradiotherapy.

Exclusion Criteria:

  • Metastasized disease.
  • Previous or concurrent malignancies.
Both
18 Years and older
No
Netherlands
 
NCT01156831
09-18-12/08
Yes
I. Steenbakkers, MD / G.Lammering, MD, PhD, MAASTRO clinic
Maastricht Radiation Oncology
Not Provided
Principal Investigator: Guido Lammering, MD PhD Radiation Oncology, Maastro Clinic
Principal Investigator: Meindert Sosef, MD PhD Atrium Hospital Heerlen
Maastricht Radiation Oncology
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP